Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality.
Francisco AguilarKevin Bryan U LoEduardo E QuinteroRicardo J TorresWikien A HungJeri C AlbanoIsabella AlvizCarlos RodriguezMario J GarciaJorge RomeroLeandro SlipczukPublished in: Expert review of cardiovascular therapy (2021)
One in every six patients received off-label DOACs dosing. Off-label dosing was associated with increased 30-day readmissions and 1-year all-cause mortality.
Keyphrases
- direct oral anticoagulants
- venous thromboembolism
- atrial fibrillation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- heart failure
- left atrial appendage
- oral anticoagulants
- left atrial
- cardiovascular events
- catheter ablation
- cardiovascular disease
- acute coronary syndrome
- coronary artery disease
- left ventricular
- patient reported outcomes